Bioavailability of oral and intramuscular phenobarbital

Journal of Clinical Pharmacology
C T ViswanathanP G Welling

Abstract

The absorption of phenobarbital was compared in healthy adult subjects after oral and intramuscular therapeutic doses. Serum levels of phenobarbital were determined for 21 days after dosing by means of radioimmunoassay. Serum levels were similar from both dosage routes, with peak levels occurring at 1-3 hours after dosing and then declining slowly with an elimination half-life of about 90 hours. The overall efficiency of phenobarbital absorption from intramuscular doses was approximately 80 per cent of that from equivalent oral doses. Except in cases where oral dosing is not appropriate, there is no clinical advantage in giving phenobarbital intramuscularly to adult patients.

References

Jan 27, 1975·Annals of the New York Academy of Sciences·M Shlafer, A M Karow
Sep 1, 1974·Clinical Pharmacology and Therapeutics·B J WilderR A Buchanan
Nov 21, 1974·The New England Journal of Medicine·D J GreenblattJ Koch-Weser
Oct 4, 1974·European Journal of Clinical Pharmacology·E KarlssonM D Rawlins
Sep 27, 1973·The New England Journal of Medicine·D J GreenblattT W Smith
Apr 1, 1973·The Journal of Obstetrics and Gynaecology of the British Commonwealth·G T McCarthyA E Robinson
Mar 1, 1966·Neurology·M Dam, V Olesen
Feb 1, 1965·The American Journal of Cardiology·J E DOHERTY, W H PERKINS

Citations

May 1, 1979·Journal of Clinical Pharmacology·C T ViswanathanP G Welling
Jan 1, 1982·European Journal of Clinical Pharmacology·A J WilenskyS P Kaluzny
Sep 3, 2013·Journal of Neurology·Wilma S W WichardsFrans S S Leijten
Sep 1, 1980·Neuropharmacology·W G SannitaG Rosadini
Jun 13, 1998·American Journal of Ophthalmology·O WeijtensJ C van Meurs
Feb 14, 2012·Advanced Drug Delivery Reviews·Gail D Anderson, Russell P Saneto
Nov 9, 2011·Advanced Drug Delivery Reviews·Cecilie Johannessen LandmarkTorbjörn Tomson
May 5, 2011·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Graham LappinColin Garner
Feb 1, 1982·Journal of Clinical Pharmacology·E NelsonD G Perrier
Jun 15, 2015·Epilepsy & Behavior : E&B·Ilo E Leppik, Sima I Patel
Jun 14, 2018·Epilepsia·Brady S MoffettSimon Y Kayyal
Jan 1, 1985·Journal of Clinical Pharmacology·T R BrowneD J Greenblatt
Oct 14, 2020·Expert Opinion on Drug Metabolism & Toxicology·Matthijs W van HoogdalemTomoyuki Mizuno

Related Concepts

Biological Availability
Intramuscular Injection
Luminal

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Systemic Juvenile Idiopathic Arthritis

Systemic juvenile idiopathic arthritis is a rare rheumatic disease that affects children. Symptoms include joint pain, as well as fevers and skin rashes. Here is the latest research on this disease.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Cell Atlas Along the Gut-Brain Axis

Profiling cells along the gut-brain axis at the single cell level will provide unique information for each cell type, a three-dimensional map of how cell types work together to form tissues, and insights into how changes in the map underlie health and disease of the GI system and its crosstalk with the brain. Disocver the latest research on single cell analysis of the gut-brain axis here.

Myocardial Stunning

Myocardial stunning is a mechanical dysfunction that persists after reperfusion of previously ischemic tissue in the absence of irreversible damage including myocardial necrosis. Here is the latest research.

Pontocerebellar Hypoplasia

Pontocerebellar hypoplasias are a group of neurodegenerative autosomal recessive disorders with prenatal onset, atrophy or hypoplasia of the cerebellum, hypoplasia of the ventral pons, microcephaly, variable neocortical atrophy and severe mental and motor impairments. Here is the latest research on pontocerebellar hypoplasia.

Central Pontine Myelinolysis

Central Pontine Myelinolysis is a neurologic disorder caused most frequently by rapid correction of hyponatremia and is characterized by demyelination that affects the central portion of the base of the pons. Here is the latest research on this disease.

Trichotillomania

Trichotillomania is an impulse control disorder characterized by the recurrent pulling of one's hair resulting in noticeable hair loss. Here are the latest discoveries in this field.

DDX3X Syndrome

DDX3X syndrome is caused by a spontaneous mutation at conception that primarily affects females due to its location on the X-chromosome. DDX3X syndrome has been linked to intellectual disabilities, seizures, autism, low muscle tone, brain abnormalities, and slower physical developments. Here is the latest research.

© 2021 Meta ULC. All rights reserved